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WS4.1 New molecular models of CFTR based on ABC transporter
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CFTR is a chloride channel belonging to the ABC superfamily. In previous work,
we have developed models of the whole 3D structure of human CFTR based
on experimental structures of proteins belonging to the ABC superfamily, in
outward and inward-facing conformations (Sav1866, Msba) (Mornon 2008 & 2009,
Serohijos 2008). These models, together with molecular dynamics (MD) simulations
based on Sav1866 (Norimatsu 2012, Dalton 2012) and PgP (Furukawa 2013), were
used to understand the molecular basis of the CFTR functioning.
Here, we present a reﬁned sequence alignment and a model of the CFTR open
channel which uses information from all ﬁve known 3D structures of ABC
exporters. This model provides a new vision of the pore and the interfaces of the
intracellular loops 1 and 3 with the NBDs. We also describe a new model of CFTR
based on the structure of the heterodimeric ABC transporter TM287-TM288 in an
inward-facing state. As CFTR, this structure has nonequivalent ATP-binding sites.
The two NBDs only partially separate, remaining in contact through an interface
involving conserved motifs that connect the two ATP-binding sites. Thus, this new
model of the CFTR closed channel allows unprecedented insights into the role of
speciﬁc amino acids, typifying the CFTR noncanonical ATP-binding site. MD has
been performed in order to relax the model and obtain a structure probably closer
to reality. The reﬁned models presented here pave the way for a search of molecules
able to ﬁx the assembly of the protein and its thermal stability, a major cause of
the low ability of CFTR to reach and stay at the plasma membrane.
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WS4.2 Exploration of the ATP binding site in CFTR-NBD1 for
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Symptomatic treatments exist for the most common CF-genotype, F508del, but
the utility of CF transmembrane conductance regulator (CFTR) as a target, has
been demonstrated by the efﬁcacy of a direct molecular modulator of patients
with the G551D mutation. The F508del mutation reduces folding efﬁciency and
thermodynamic stability of the ﬁrst nucleotide binding domain (NBD1) and also
interferes with interactions of NBD1 with other CFTR domains, e.g. ICDs.
Recent studies show that suppressor mutations, when expressed on the F508del-
NBD1 background, are able to enhance the thermal stability of the mutant domain
and to partially rescue DF508-CFTR. These results suggest that DF508-NBD1 is a
viable target for DF508-CFTR rescuing through the pharmaceutical intervention of
CFTR modulators binding to speciﬁc sites on this domain. Detailed computational
analysis of the characteristics of such sites may lead to identiﬁcation of drug-like
compounds that may ultimately rescue DF508-CFTR.
Here we describe a computational methodology for predicting the binding afﬁnity
of potential modulators to the ATP binding site of wildtype and mutant CFTR
NBD1. First we dock a selected set of ATP analogues into the ATP site of wildtype
(1R0X) and mutant (1XMG) NBD1 by means of in-site conformational search.
Next, the lowest energy pose of each analogue is selected and further scored
by its ability to form favorable interactions with binding site residues in accord
with a pre-suggested binding hypothesis. Our afﬁnity predictions were validated
by melting temperature (TM) analysis of NBD1-ligand. The proposed methodology
could therefore be applied to the design new CFTR modulators.
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In the absence of high-resolution structures for CFTR, deletion mutants are highly
relevant to understand how certain protein regions affect CFTR maturation and
function. The presence of two NBD1 regions which are absent from other ABC
transporters − the regulatory extension (RE) and regulatory insertion (RI) − shown
to be conformationally dynamic in F508del-NBD1-CFTR and more hidden in wt-
NBD1-CFTR, may contribute to the low folding efﬁciency of the mutant through
exposure of hydrophobic surfaces.
Our goal was to assess the impact of removing RE and RI (separately and jointly)
on the in vivo processing and function of full-length wt- and F508del-CFTR.
Our data show that removal of RI alone, or together with RE, from F508del-CFTR
restores both maturation and function to the levels of wt-CFTR, suggesting that
these variants acquire a native (fully folded) conformation in vivo. We also evaluated
the effect of known F508del-revertant mutations (R1070W, G550E) on maturation
of DRE and DRI variants. Both revertants failed to rescue F508del-DRE-CFTR
processing, but further increase F508del-DRI-CFTR processing. VX-809 did not
signiﬁcantly rescue DRE, but it signiﬁcantly increased rescue of all DRI-F508del-
CFTR variants. Most of the variants respond less to VX-770 than to Genistein as
a channel potentiator.
Additional studies on maturation efﬁciency and functional characterization of these
CFTR and other DRE/DRI variants with CFTR modulators are underway to further
elucidate their impact on CFTR structure.
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Cystic Fibrosis (CF) is due to mutations in the gene encoding the CFTR ion channel.
The most common is the deletion of a phenylalanine in position 508 (DF508-CFTR).
This results in a channel which is partially functional but is retained and degraded
in the endoplasmic reticulum (ER) due to a defect in the trafﬁcking towards plasma
membrane. It was previously shown that cytokeratin 8 (K8) level is increased in cells
expressing DF508-CFTR (Davezac et al., Proteomics 2004), and a more recent study
showed that K8 strongly interacts with DF508-CFTR, contributing to the retention
of the channel in the ER. Furthermore, it was observed that K8 ablation by siRNA
led to restoration of CFTR-dependent conductance in vitro and in vivo, suggesting
that K8 is a potential therapeutic target in CF (Colas et al., Hum.Mol.Genet. 2012).
We hypothesized that the intracellular delivery of antibodies directed against K8
into DF508-CFTR expressing cells could also disrupt the interaction between K8
and mutant CFTR, and restore its trafﬁc.
We developed a novel liposome-based system for the delivery of proteins into living
cells and showed its ability to deliver an antibody directed against K8, leading to
the labeling of the keratin cytoskeleton into living cells. By monitoring halide
efﬂux in treated cells, we observed the appearance of a conductance compatible
with CFTR activity, suggesting the ability of the delivered antibodies to disrupt the
interaction between K8 and F508D-CFTR and consequently to restore the trafﬁc of
F508D-CFTR.
This original protein-based strategy could provide a new tool to CF researchers and
contribute to the development of biotherapies against this pathology.
